The treatment of relapsed or refractory leukemias and lymphomas continues to be challenging, often characterized by limited therapeutic options and poor outcomes. Effective new therapies are needed for these patients.
Chimeric antigen receptor (CAR) T-cell therapy represents a radical departure from current treatments by simultaneously being cell therapy, gene therapy, and immunotherapy. It promises to revolutionize the treatment of multiple hematologic malignancies, including relapsed or refractory B-cell acute lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and others.
This activity will review CAR T-cell therapy’s biologic rationale and mechanism of action, the latest efficacy and safety data in different patient populations, and how to effectively manage potentially severe toxicities to maximize patient outcomes.
This activity is a web-based, on-demand activity, featuring an expert panel discussion. This activity is designed as a forum for the debate and evaluation of the most recent clinical data, and to provide evidence-based updates and expert insights on the discussion points to translate current and emerging evidence into real-world clinical practice.